General Information
Ibrutinib is an orally administered anticancer drug for the treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and Waldenstrm’s macroglobulinemia (WM ‘ also known as lymphoplasmacytic lymphoma).
About the API
Trade name(s)
Imbruvica
Technology
Synthetic
Therapeutic category
Oncology
Available formulations
Oral Solid
Regulations
US DMF
US DMF